Core Viewpoint - The announcement details a reduction in shareholding by a major shareholder of Shanghai Haoyuan Pharmaceutical Co., Ltd., specifically the Su Min Investment Junxin (Shanghai) Industrial Upgrade and Technology Innovation Equity Investment Partnership (Limited Partnership), which has decreased its stake to below 5% as part of a previously disclosed share reduction plan [1][2][3] Summary by Sections 1. Basic Information of the Shareholder - The shareholder involved is Su Min Investment Junxin (Shanghai) Industrial Upgrade and Technology Innovation Equity Investment Partnership (Limited Partnership) with a registered address in Shanghai and a capital contribution of RMB 1.161 billion [1][2] 2. Details of the Shareholding Change - The shareholder has reduced its holdings by 2,031,426 shares, which accounts for 0.96% of the company's total share capital [1][2] - Post-reduction, the shareholder holds 10,547,990 shares, representing 5.00% of the total shares, down from 12,579,416 shares or 5.96% prior to the reduction [2][3] 3. Impact of the Shareholding Change - The reduction in shareholding does not trigger a mandatory tender offer and will not result in a change of the company's controlling shareholder or actual controller [1][3] - The company's governance structure and ongoing operations are not expected to be significantly affected by this change [3]
皓元医药: 上海皓元医药股份有限公司关于持股5%以上股东持股比例降至5%的权益变动提示性公告